Table 3.
Intratumor Staining Distribution of the Mutated Protein in Patients with BRAFT1799A and Strong (3+) Immunostaining According to Tumor Type
| Tumor Type | Distribution of IHC Staining in the Tumor | ||
|---|---|---|---|
| <50% + Cells Heterogeneous | 50%−79% + Cells Heterogeneous | ≥80% + Cells Homogeneous | |
| PTC (n = 14)a | 0 | 1 (7) | 13 (93) |
| PDTC (n = 3)a | 0 | 0 | 3 (100) |
| ATC (n = 14)a | 1 (7) | 1 (7) | 12 (86) |
| All thyroid carcinomas (n = 31) | 1 (3.3) | 2 (6.4) | 28 (90.3) |
Data are n (%).
a
In 2 PTCs and 1 ATC, intratumoral staining distribution was not assessable.